Status In progress
Process CDF Review
ID number 1559

Provisional Schedule

Expected publication 06 May 2020

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Associated guideline groups National Guideline Alliance
Comparator companies Roche Products (erlotinib) (Confidentiality agreement signed, participating)
  Accord Healthcare (docetaxel) (Confidentiality agreement not signed, not participating)
  Hospira UK (docetaxel) (Confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (docetaxel) (Confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
18 March 2020 Committee meeting: 1
15 October 2019 In progress, Appraisal in progress.
03 September 2019 This appraisal topic is paused to allow the company to provide updated submission documentation. The appraisal will be rescheduled into the work programme and the updated appraisal timelines will be communicated, once known.
19 July 2019 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance